.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
McKesson
Colorcon
US Army
Boehringer Ingelheim
Medtronic
Citi
Healthtrust
Dow
Julphar

Generated: July 23, 2017

DrugPatentWatch Database Preview

ATACAND Drug Profile

« Back to Dashboard

Which patents cover Atacand, and when can generic versions of Atacand launch?

Atacand is a drug marketed by Astrazeneca and is included in two NDAs.

The generic ingredient in ATACAND is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.

Summary for Tradename: ATACAND

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list7
Bulk Api Vendors: see list72
Clinical Trials: see list38
Patent Applications: see list2,060
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ATACAND at DailyMed

Pharmacology for Tradename: ATACAND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-001Jun 4, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca
ATACAND HCT
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL021093-003May 16, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-004Jun 4, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-002Jun 4, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-003Jun 4, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ATACAND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-002Jun 4, 1998► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-004Jun 4, 1998► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-001Jun 4, 1998► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-004Jun 4, 1998► Subscribe► Subscribe
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838-001Jun 4, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ATACAND

Drugname Dosage Strength RLD Submissiondate
candesartan cilexetil and hydrochlorothiazideTablets32 mg/25 mgAtacand HCT3/6/2009
candesartan cilexetil and hydrochlorothiazideTablets16 mg/12.5 mg and 32 mg/12.5 mgAtacand HCT6/25/2008
candesartan cilexetilTablets4 mg, 8 mg, 16 mg and 32 mgAtacand12/22/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
UBS
McKinsey
Healthtrust
Queensland Health
Boehringer Ingelheim
Novartis
Cipla
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot